A PHASE 1, NON-RANDOMIZED, OPEN-LABEL, SINGLE-DOSE, PARALLEL GROUP STUDY TO COMPARE THE PHARMACOKINETICS OF VEPDEGESTRANT (PF-07850327) IN ADULT PARTICIPANTS WITH MODERATE AND SEVERE HEPATIC IMPAIRMENT RELATIVE TO HEALTHY PARTICIPANTS WITH NORMAL HEPATIC FUNCTION

The purpose of the study is to look at how the body processes a study medicine called vepdegestrant in participants with loss of liver function relative to people with normal liver function.
This study is seeking participants who are:
* females who cannot have children or males
* between 18 and 70 years of age
* weigh more than 50 Kilograms (110 pounds)
* either healthy with normal liver function or have loss of liver function
All participants in this study will take one dose of vepdegestrant by mouth. This study looks at how the medicine is changed and removed from the body after being taken by the participants. The amount of vepdegestrant in participants with loss of liver function will be compared to the amount of vepdegestrant in participants with normal liver function.
All participants will stay at the study clinic for about 11 days and 10 nights.

Start Date18 Nov 2025

Sponsor / Collaborator

Pfizer Inc.

[+1]

NCT06911788

/ CompletedPhase 1

A PHASE 1, OPEN-LABEL, FIXED SEQUENCE, 2-PERIOD, SINGLE-DOSE, CROSS-OVER STUDY TO ESTIMATE THE ABSOLUTE BIOAVAILABILITY OF VEPDEGESTRANT (ARV-471, PF-07850327) FOLLOWING ORAL AND INTRAVENOUS DOSING OF THE DRUG TO HEALTHY PARTICIPANTS

The purpose of this study is to learn how much of the study medicine called Vepdegestrant will reach the bloodstream when given orally compared to given intravenously.
This study is seeking participants who:
* are healthy males and healthy females who cannot have children.
* are 18 years or older.
* are healthy as decided by medical tests.
* have a body mass index (BMI) of 16 to 32 kilogram per meter squared.
* have a total body weight of more than 45 kilograms (99 pounds).
In Period 1, all participants will receive one dose of Vepdegestrant by IV. In Period 2, all participants will receive one dose of Vepdegestrant by mouth following a high-fat breakfast. The levels of Vepdegestrant in Period 1 will be compared to the levels of Vepdegestrant in Period 2 and the bioavailablility of the oral formulation of Vepdegestrant will be determined.
The study duration is 22 days and includes two periods. Participants will stay in the clinical research unit for 9 days (8 nights) during each period. A follow-up visit for each participant takes place at 28 to 35 days after taking the study medicine for the last time.

Start Date03 Apr 2025

Sponsor / Collaborator

Pfizer Inc.

[+1]

NCT06645938

/ CompletedPhase 1

A PHASE I, RANDOMIZED, OPEN-LABEL, 2-PERIOD, 2-TREATMENT, 2-SEQUENCE, CROSSOVER, SINGLE-DOSE STUDY IN HEALTHY ADULT PARTICIPANTS TO ESTIMATE THE BIOAVAILABILITY OF AN VARIANT (HIGH HARDNESS) TABLET OF VEPDEGESTRANT (ARV-471, PF-07850327) RELATIVE TO THE REGISTRATIONAL TABLET

The purpose of the study is to compare the amount vepdegestrant available from two different tablet formulations under fed conditions in healthy adult participants; 200 mg vepdegestrant alternative tablet formulation compared to 200 mg vepdegestrant standard tablet formulation.
This study is seeking male or female participants of non-childbearing potential age who:
* are 18 years or older
* are healthy as decided by medical tests.
* have a Body mass index (BMI) of 16 to 32 kilogram per meter squared; and a total body weight of more than 45 kilograms (99 pounds).
All participants will be put into groups to receive one of the 2 treatments in each period. This study will consist of 2 treatment sequences:
* Sequence 1: Single 200 mg dose of vepdegestrant registrational tablet in Period 1, followed by a single 200 mg dose of vepdegestrant variant tablet in Period 2.
* Sequence 2: Single 200 mg dose of vepdegestrant variant tablet in Period 1, followed by a single 200 mg dose of vepdegestrant registrational tablet in Period 2.
Participants will be in the study for about 11 weeks.

Start Date16 Oct 2024

Sponsor / Collaborator

Pfizer Inc.

[+1]

100 Clinical Results associated with Vepdegestrant

100 Translational Medicine associated with Vepdegestrant

100 Patents (Medical) associated with Vepdegestrant

Literatures (Medical) associated with Vepdegestrant

01 Jun 2026·CLINICAL THERAPEUTICS

Letter to the Editor Regarding “The Effect of Itraconazole on the Pharmacokinetics of Vepdegestrant, a PROteolysis TArgeting Chimera Estrogen Receptor Degrader, in Healthy Adult Participants” Recently Published by Tran and Colleagues

Letter

Author: Dahlgren, David ; Lennernäs, Hans ; Niessen, Janis

01 Jun 2026·CLINICAL THERAPEUTICS

Response to Letter to the Editor Regarding “The Effect of Itraconazole on the Pharmacokinetics of Vepdegestrant, a PROteolysis TArgeting Chimera Estrogen Receptor Degrader, in Healthy Adult Participants”

Letter

Author: Stouffs, Alexandre ; Tan, Weiwei ; Tran, Lana ; Lee, Kimberly C ; Zhang, Yuanyuan ; Matschke, Kyle T ; Winton, Jennifer A

01 Jun 2026·MOLECULAR PHARMACEUTICS

The In Vivo Effect of Amorphous Drug Nanoprecipitates on the Intestinal Absorption of the PROTACs ARV-110 (Bavdeglutamide) and ARV-471 (Vepdegestrant)

Article

Author: Koziolek, Mirko ; Indulkar, Anura ; Borchardt, Thomas ; Dahlgren, David ; Sjöblom, Markus ; Hedeland, Mikael ; Niessen, Janis ; Lennernäs, Hans

Targeted degradation of disease-associated proteins via proteolysis-targeting chimeras (PROTACs) is a powerful pharmacological strategy, but it requires a complex molecular architecture associated with poor intestinal absorption. Rational development of orally bioavailable PROTACs requires a thorough understanding of their biopharmaceutical properties. This mechanistic in vivo study aimed to address the potential of colloidal particle formulations to enhance the intestinal absorption of two model PROTACs, ARV-110 and ARV-471. Dose escalation studies were conducted in rats to investigate the impact of particle size and concentration on intestinal absorption and bioavailability of the PROTACs. The contribution of colloidal amorphous drug nanoprecipitates was moreover directly quantified by comparing intestinal absorption from a colloid-forming formulation with that of an amorphous, noncolloidal counterpart. All in vivo experiments were complemented by in vitro determinations of amorphous solubility, solubilization dynamics, and characterization of the size and solid state of the emerging colloidal particles. The two PROTACs consistently formed luminally stable, amorphous drug nanoprecipitates in vivo. Dose-proportional increases in absorption were observed at concentrations up to 15-fold above their amorphous solubility. The amorphous drug nanoprecipitates directly contributed to an enhanced absorptive flux up to 7-fold compared to a noncolloidal amorphous powder. The potentiating effect was attributed to particle drifting of the nanoparticles across the aqueous boundary layer, which increased the free drug concentration at the epithelial membrane. For the less soluble ARV-110, the colloid effect was capped at doses >0.2 mg/kg due to saturation. For the more soluble ARV-471, the colloid effect persisted at doses up to 5.0 mg/kg but at a reduced rate due to the formation of larger, less mobile particles. Overall, this work provided mechanistic insight into PROTAC absorption and suggested that formulations capable of generating stable amorphous drug nanoprecipitates represent a promising strategy to enhance the oral bioavailability of low-solubility PROTACs.

157

News (Medical) associated with Vepdegestrant

01 Jul 2026

·www.biospace.com

Rigel Appoints Board Member Alison L. Hannah, M.D. as Chief Medical Officer

Dr. Hannah has decades of oncology drug development experience and has served on Rigel's Board of Directors since 2021 She has resigned from Rigel's Board of Directors to join the company SOUTH SAN FRANCISCO, Calif. , July 1, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced the appointment of Alison L. Hannah, M.D. to the role of Executive Vice President and Chief Medical Officer. Dr. Hannah has resigned from Rigel's Board of Directors, effective July 1, 2026, in connection with her appointment. She succeeds Lisa Rojkjaer, M.D., as Chief Medical Officer. "Alison has been a valued member of Rigel's Board, and we are pleased to welcome her to the executive leadership team as Chief Medical Officer at an exciting time for Rigel. Her deep experience leading oncology clinical development and advancing investigational therapies through the regulatory process will be extremely valuable as we continue to advance our development pipeline, including R289 in lower-risk MDS, vepdegestrant in metastatic breast cancer and other potential opportunities," said Raul Rodriguez, Rigel's president and CEO. "On behalf of the entire Rigel team, I want to sincerely thank Lisa for her dedication and many contributions to the company." Rigel's leading pipeline asset, R289 1 , a potent and selective dual inhibitor of interleukin receptor-associated kinases 1 and 4 (IRAK1/4), continues to be advanced in its Phase 1b clinical study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with relapsed or refractory lower-risk myelodysplastic syndrome (MDS). Enrollment in the dose expansion phase of the study is ongoing, and Rigel remains on track to complete enrollment and select the recommended Phase 2 dose for future clinical studies in the second half of 2026. The company continues to anticipate sharing preliminary data from the dose expansion phase of the study by the end of 2026. In addition, Rigel is progressing its evaluation of other potential indications to advance R289 and is planning to provide an update later this year. "I am excited to join Rigel at this important stage in the company's evolution. Having served on Rigel's Board, I have seen firsthand the strength of the team, the scientific rationale behind its programs and the opportunity to advance meaningful new therapies for patients with hematologic disorders and cancer," said Dr. Hannah. "I look forward to working closely with the leadership team to help guide the continued development of R289 and Rigel's broader clinical strategy, including the recent addition of vepdegestrant." About Dr. Hannah Alison L. Hannah, M. D. has been appointed Executive Vice President and Chief Medical Officer (CMO) of Rigel. She resigned from Rigel's Board of Directors, which she had served on since May 2021, in connection with her appointment as CMO. Previously, Dr. Hannah has held the roles of Chief Medical Officer of CytomX Therapeutics, where she oversaw clinical development of conditionally activated protein therapeutics, and Senior Medical Director at SUGEN, Inc. (acquired by Pharmacia & Upjohn, now Pfizer), where she had oversight of clinical development, clinical operations, and pharmacovigilance, specializing in the development of tyrosine kinase inhibitors, including sunitinib (SUTENT) approved for the treatment of kidney cancer and imatinib-refractory gastrointestinal stromal tumors. Dr. Hannah has served as a consultant to the pharmaceutical and biotechnology industry since 2000, directing the development of investigational cancer therapies. In this capacity, Dr. Hannah has successfully filed over 40 regulatory applications for first-in-human clinical testing and has played significant roles in the broad marketing approval of multiple anticancer therapeutics. Dr. Hannah began her career at Quintiles, a global contract research organization, where she specialized in overseeing early to registrational-stage oncology clinical trials. She has served since June 2015 on the Board of Directors for Neogenomics, a cancer diagnostic firm. Dr. Hannah received her B.A. in biochemistry and immunology from Harvard University and her M.D. from the University of St Andrews. About Rigel Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, the Company's marketed products and pipeline of potential products, visit . R289 is an investigational compound not approved by the FDA. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 relating to, among other things, Rigel's clinical development plans and the potential of its product candidates, including R289; the anticipated timing of enrollment completion, dose selection and preliminary data from the ongoing Phase 1b clinical study of R289 in patients with relapsed or refractory lower-risk myelodysplastic syndrome (MDS); the evaluation of additional potential indications for R289; the advancement of Rigel's broader development pipeline, including vepdegestrant; and the expected contributions of Dr. Alison L. Hannah as Rigel's Chief Medical Officer. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "anticipates," "believes," "expects," "intends," "may," "plans," "potential," "will," and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are based on Rigel's current beliefs, expectations and assumptions and involve risks and uncertainties that are difficult to predict and, in many cases, are beyond Rigel's control. Actual results may differ materially from those expressed or implied by these forward-looking statements due to a variety of factors, including, without limitation, risks associated with the timing, progress and results of Rigel's clinical trials; the ability to successfully develop and obtain regulatory approval for product candidates; the availability of funding for development activities; the occurrence of unforeseen safety or efficacy findings; the ability to enroll patients in clinical trials; competition from other therapies; reliance on third parties for clinical development, manufacturing and other services; changes in applicable laws or regulations; and other risks described from time to time in Rigel's filings with the Securities and Exchange Commission, including the "Risk Factors" section of Rigel's most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. Any forward-looking statement in this press release speaks only as of the date on which it is made. Rigel undertakes no obligation to update or revise any forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law. Contact for Investors & Media: Investors: Rigel Pharmaceuticals, Inc. 650.624.1232 ir@rigel.com Media: David Rosen Argot Partners 646.461.6387 david.rosen@argotpartners.com View original content to download multimedia: SOURCE Rigel Pharmaceuticals, Inc.

23 Jun 2026

·www.biospace.com

Entact Bio Appoints John G. Houston, Ph.D., to its Board of Directors

John G. Houston, Ph.D. Entact Bio Appoints John G. Houston, Ph.D., to its Board of Directors A veteran biopharma innovator who helped advance the first FDA-approved PROTAC drug, Dr. Houston will strengthen Entact's leadership in induced-proximity therapeutics. Dr. Houston's deep experience with protein degraders will be invaluable to supporting Entact’s development of ENTAC™ medicines, which leverage the same underlying induced-proximity mechanism as PROTAC protein degraders to achieve the opposite effect: enhancing the function of beneficial proteins. The appointment bolsters Entact's efforts to advance its Encompass™ platform and pipeline of protein-enhancing ENTAC medications, opening up a new way of treating loss-of-function disease. Watertown, MA, June 23, 2026 – Entact Bio, a developer of precision medicines that enhance the function of beneficial proteins, today announced that John G. Houston, Ph.D., has been appointed as Independent Director to Entact’s Board. Dr. Houston is a veteran biopharma leader who helped build the scientific and clinical foundation for proximity-inducing drugs, a new class of medicines that bring two different proteins together to produce a therapeutic effect. “We are delighted to have Dr. Houston join us. John helped build Arvinas into the company that earned the first-ever FDA approval for a type of proximity-inducing drugs called PROTACs (Proteolysis-Targeting Chimera), with Veppanu (vepdegestrant) recently approved. His scientific depth and his experience taking a novel mechanism from concept to approval make him invaluable as we advance ENTACs (ENhancement-TArgeting Chimeras) toward patients,” said Richard Gaster, Managing Partner at venBio Partners and Chair of Entact’s Board of Directors . “John’s experience advancing a first-in-class induced proximity mechanism from concept to approved medicine is directly relevant to what we are building at Entact,” said Victoria Richon, CEO of Entact Bio . “We are thrilled to have him join our Board as we advance our Encompass platform and ENTAC pipeline.” Dr. Houston served as President, Chief Executive Officer (CEO), and Chair of the Board of Directors at Arvinas, where he led the advancement of multiple PROTAC programs into clinical development and currently serves on its Board of Directors. Prior to Arvinas, he spent more than 18 years in roles of increasing responsibility at Bristol Myers Squibb (BMS), where as part of the R&D leadership team he contributed to advancing more than 200 compounds into early development, several of which progressed into late-stage clinical trials. Before BMS, he served as Head of the Lead Discovery Unit at Glaxo Wellcome Research and Development. “PROTACs demonstrated that induced proximity holds vast therapeutic potential,” said Dr. Houston. “PROTACs direct that power toward degrading harmful proteins. ENTACs, on the other hand, direct it toward enhancing beneficial ones. I am excited to join Entact’s efforts to apply this principle to loss-of-function diseases, conditions that have long been out of reach for conventional therapeutics. The opportunity here is substantial.” Dr. Houston earned a B.Sc. in Medical Microbiology from the University of Glasgow and a Ph.D. in Microbial Biochemistry from Heriot-Watt University, Edinburgh. He also completed postdoctoral research at the University of Glasgow on a Medical Research Council (MRC) grant. About Entact Bio Entact Bio is developing a novel class of precision medicines that enhance the function of beneficial proteins. Launched by a founding team deeply rooted in deubiquitylase (DUB) biochemistry, chemical biology, disease biology, and small-molecule drug development, Entact has built its proprietary Encompass™ platform to create ENhancement-TArgeting Chimeric (ENTAC™) medicines. ENTACs leverage the natural ability of DUBs to regulate and enhance protein function. By harnessing the power of DUBs, Entact is expanding the universe of treatable diseases and creating new options for patients who are underserved by current therapeutic modalities. For more information, visit entactbio.com . Media contact media@entactbio.com Attachment John G. Houston, Ph.D.

Executive Change

17 Jun 2026

·allsci.com

Rigel closes USD 70m Veppanu deal with Arvinas and Pfizer

Rigel Pharmaceuticals (Nasdaq: RIGL) has closed its exclusive global license for Veppanu (vepdegestrant), paying USD 70 million upfront to Arvinas (Nasdaq: ARVN) and Pfizer (NYSE: PFE) — each receiving USD 35 million — for the first FDA-approved PROTAC in history. The deal, effective June 11, transfers commercialization rights for an approved oral estrogen receptor degrader to the San Francisco-based Rigel, a biotech with no prior presence in breast cancer. Rigel expects to launch Veppanu commercially in August 2026. The closing follows the original agreement announced May 12, 2026, under which Rigel will pay an additional USD 15 million upon completion of manufacturing and development transition activities, contribute up to USD 40 million toward ongoing development activities over four years, and is eligible to pay up to USD 320 million in regulatory and commercial milestones. Arvinas and Pfizer are entitled to tiered royalties ranging from mid-teens to mid-twenties percent on net sales, plus a share of sublicensing revenue Rigel generates outside the US. Vepdegestrant is the first approved PROTAC therapy, designed to degrade rather than simply inhibit the estrogen receptor. FDA approval on May 1, 2026 was based on data from VERITAC-2 (NCT05654623), a global, randomized Phase III trial comparing vepdegestrant to fulvestrant in patients with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer. The deal’s economics are strikingly compressed relative to the asset’s history. When Pfizer originally partnered with Arvinas in July 2021 for vepdegestrant’s co-development, Pfizer paid USD 650 million upfront under a deal worth up to USD 1.4 billion plus a 50/50 profit share. Rigel’s USD 70 million upfront — for a post-approval, global asset — represents roughly a 90% discount from that original payment, highlighting the difference between the economics of an early-stage development partnership and a commercial-stage asset with a defined label. The drug enters an increasingly competitive ESR1-mutated breast cancer market that already includes approved oral estrogen receptor-targeting therapies elacestrant (Orserdu) and imlunestrant (Inluriyo), while AstraZeneca’s camizestrant has an FDA decision pending. Veppanu’s PROTAC mechanism offers theoretical differentiation through complete protein degradation, but no head-to-head clinical data against the approved SERDs have been reported. For Rigel, the transaction is a meaningful step-up in scope. Its prior commercial-stage acquisition — US rights to Gavreto (pralsetinib) from Blueprint Medicines in February 2024 for up to USD 102.5 million in milestones plus tiered royalties of 10%–30% — was US-only. Veppanu is Rigel’s first global license and its first oncology asset outside hematology. Notably, Eli Lilly terminated its USD 960 million ocadusertib collaboration with Rigel in April 2026, weeks before the Veppanu deal was announced, removing Rigel’s largest development partnership and creating both financial and strategic impetus to replace it with a commercial-stage asset. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/ Your email address will not be published. Required fields are marked * Comment * Name * Email * Website Privacy Terms About Us Copyright © 2026. AllSci Corp. All rights reserved.

100 Deals associated with Vepdegestrant

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
ER-positive/HER2-negative/ ESR1-mutated breast cancer	United States	Rigel Pharmaceuticals, Inc.	01 May 2026

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced breast cancer	Phase 3	United States	Arvinas Estrogen Receptor, Inc.	09 Aug 2023
Advanced breast cancer	Phase 3	United States	Pfizer Inc.	09 Aug 2023
Advanced breast cancer	Phase 3	China	Pfizer Inc.	09 Aug 2023
Advanced breast cancer	Phase 3	China	Arvinas Estrogen Receptor, Inc.	09 Aug 2023
Advanced breast cancer	Phase 3	Japan	Arvinas Estrogen Receptor, Inc.	09 Aug 2023
Advanced breast cancer	Phase 3	Japan	Pfizer Inc.	09 Aug 2023
Advanced breast cancer	Phase 3	Australia	Pfizer Inc.	09 Aug 2023
Advanced breast cancer	Phase 3	Australia	Arvinas Estrogen Receptor, Inc.	09 Aug 2023
Advanced breast cancer	Phase 3	Brazil	Arvinas Estrogen Receptor, Inc.	09 Aug 2023
Advanced breast cancer	Phase 3	Brazil	Pfizer Inc.	09 Aug 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05548127 (TACTIVE-U, ASCO2026)	Phase 1/2	ESR1-mutated \| ER+/human epidermal growth factor receptor 2-negative (HER2−)	37	AbemaciclibVepdegestrant + AbemaciclibVepdegestrant	georugjofz(swsewjdfez) = cqrlgiwekw boemqofzkm (yaapfktnje, 18.0 - 46.9) View more	Positive	29 May 2026
				Abemaciclib (ESR1m)	georugjofz(swsewjdfez) = hsrcdncmxo boemqofzkm (yaapfktnje, 25.8 - 65.8) View more
AACR2026	Phase 2/3	Hormone receptor positive HER2 negative breast cancer HR Positive \| HER2 Negative	16	Imlunestrant alone	uctynninke(dlvzvutdjo) = mkdjpuqrdp xddrvzsfjc (vasjlgaqex ) View more	Positive	21 Apr 2026
				Camizestrant 75mg	uctynninke(dmcoeexdmt) = djetndgdsu eebewspnaw (pfdxlkdzhg ) View more
NCT05654623 (VERITAC-2, CTgov)	Phase 3	ER-positive/HER2-negative Breast Cancer	624	fulvestrant	cezktcayrc(gzuznaymie) = zjhjrqzvep ajilszbmxx (jlbxhutefn, blzkmfdoml - jdnalecktn) View more	-	03 Feb 2026
NCT04072952 (SABCS2025)	Phase 1/2	ER-positive/HER2-negative Breast Cancer ESR1 mutation	138	Vepdegestrant (ER-positive/HER2-negative advanced breast cancer)	sgsixpovfv(hlfsnbvuie) = bposprpjyf uvdoggrudx (htpaoqqbkq ) View more	Positive	10 Dec 2025
NCT05549505 (TACTIVE-N, CTgov)	Phase 2	ER-positive/HER2-negative Breast Cancer	152	Surgical resection of breast tumor+ARV-471 (Arm A: ARV-471 (Experimental))	weawzbozkk = dtaujrmtwe zlpdxdnxcb (mtegcovxge, abzthwbaxe - hipzegaesn) View more	-	29 Aug 2025
				Surgical resection of breast tumor+anastrozole (Arm B: Anastrozole)	weawzbozkk = jctxatnqzb zlpdxdnxcb (mtegcovxge, jyaazebyjj - hjfxwmvxuy) View more
NCT05654623 (VERITAC-2, Pubmed \| N Engl J Med)	Phase 3	Advanced breast cancer	624	Vepdegestrant 200 mg	iegcrmtaxl(psdkofzktt) = in 2.9% and 0.7% of the patients, respectively kfiokecuhv (ozmucqwtpt ) View more	Positive	07 Aug 2025
				Fulvestrant 500 mg
NCT05654623 (VERITAC-2, ASCO2025 \| Company_Website) Manual	Phase 3	ER-positive/HER2-negative Breast Cancer ER Positive \| HER2 Negative	624	Vepdegestrant	xnftihzozn(zzjtpecykj) = vhdyqfnngd esclhfytdc (grytfvchvn, 3.6–5.3) View more	Positive	30 May 2025
				fulvestrant	xnftihzozn(zzjtpecykj) = wiriegoswe esclhfytdc (grytfvchvn, 2.2–3.8) View more
NCT05654623 (VERITAC-2, Company_Website) Manual	Phase 3	ER-positive/HER2-negative Breast Cancer ESR1 Mutation	-	Vepdegestrant (ESR1 mutant)	xagjxufwli(dgcgpvkxfp) = The results exceeded the pre-specified target hazard ratio of 0.60 in the ESR1m population. The trial did not reach statistical significance in improvement in PFS in the intent-to-treat (ITT) population. eargkxqryl (zzhdhkzeby )	Negative	11 Mar 2025
				fulvestrant (ESR1 mutant)
NCT05548127 (TACTIVE-U, GlobeNewswire) Manual	Phase 1	ER-positive/HER2-negative Breast Cancer Third line	16	Vepdegestrant + Abemaciclib	zyofdsjdwt(phgzjoqxjs) = None ttrnshgzix (xxiaqayyjb ) View more	Positive	10 Dec 2024
				Vepdegestrant + Abemaciclib (mutant ESR1)
NCT05463952 (Pubmed \| Int J Clin Oncol)	Phase 1	Locally Advanced Unresectable Breast Carcinoma \| Breast Cancer \| Estrogen receptor positive breast cancer ... estrogen receptor (ER) View more	6	Vepdegestrant 200 mg QD	wpwgajthfb(rvviqrgtyk) = Four (66.7%) patients experienced adverse events; none led to dose reduction or discontinuation rxdnkgubpy (xpjivvzxle ) View more	-	20 Nov 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis